A Crystallographic Approach for Understanding the Recognition Mechanism of Thrombin and G-quadruplex Aptamers

Filomena Sica^{1,2,3}

¹ Department of Chemical Sciences, University of Naples Federico II, Via Cintia, I-80126 Naples, Italy, ²Institute of Biostructures and Bioimaging, CNR, Via Mezzocannone, 16, I-80134 Naples, Italy, ³National Institute of Biostructures and Biosystems - Interuniversity Consortium, Viale delle Medaglie d'Oro 305, I- 00136 Rome, Italy.

(filomena.sica@unina.it)

Human-thrombin, a serine protease that maintains blood hemostasis by balancing pro- and anti-coagulant actions is an example of protein with multiple binding sites¹. In addition to the active site, the enzyme possesses two electropositive regions, in near-opposition on the protein surface, known as exosite I and exosite II, respectively. These two regions have a primary role in the regulation of enzymatic activity since they can bind molecules with diverse functions²⁻⁴. Given its central role in the clot formation, thrombin is an attractive target for the development of agents that effectively interfere with thrombogenesis. A special class of thrombin synthetic ligands is represented by nucleic acid aptamers adopting G-quadruplex structures. HD1, a 15-mer oligonucleotide recognizing exosite I⁵, and HD22, a 29-mer binding exosite II⁶, are the most studied thrombin binding aptamers and show high affinity toward their target (K_d (HD1) \approx 100 nM; K_d(HD22) \approx 0.7 nM). The increased interest in the use of DNA aptamers as drugs has stimulated the search of HD1 and HD22 variants with improved properties. In particular, the bimodular oligonucleotides RE31⁷ and NU172⁸, which have been obtained by addition of a duplex motif to the HD1 quadruplex module, show higher affinity for thrombin and anticoagulant activity, and a slower disappearance rate in human plasma in comparison with HD1.

Here I will present the most relevant results regarding the elucidation of the interactions, which govern the recognition between thrombin and DNA G-quadruplex aptamers⁹⁻¹⁴.

- 2. Bode W., Blood Cells Mol Dis, 36, 122-130, (2006).
- 3. Bode W., Mayr I., Baumann U., Huber R., Stone S.R., Hofsteenge, J. EMBO J, 8, 3467-3475, (1989).
- 4. Bode W., Turk D., Karshikov A., Protein Sci, 4, 426-471, (1992).
- 5. Bock L. C., Griffin, L. C., Latham J. A., Vermaas E. H., Toole J. J., Nature, 355, 564-566, (1992).
- 6. Tasset D. M., Kubik M. F., Steiner W., J Mol Biol, 272, 688-698, (1997).

7. Mazurov A.V., Titaeva E.V., Khaspekova S.G., Storojilova A.N., Spiridonova V.A., Kopylov A.M., Dobrovolsky, A.B. Bulletin of experimental biology and medicine, 150, 422-425, (2011).

- 8. Waters E.K., Richardson J., Schaub R.G., Kurz J.C., J Thromb Haemost, PP-WE-168, (2009).
- 9. Russo Krauss I., Merlino A., Giancola C., Randazzo A., Mazzarella L., Sica, F., Nucleic Acids Res, 39, 7858-7867, (2011).
- 10. Russo Kraus, I., Merlino A., Randazzo A., Novellino E., Mazzarella L., Sica, F., Nucleic Acids Res, 40, 8119-8128, (2012).
- 11. Pica A., Russo Krauss I., Merlino A., Nagatoishi S., Sugimoto N., Sica, F., FEBS Journal, 280, 6581-6588, (2013).
- 12. Russo Krauss I., Pica A., Merlino A., Mazzarella L., Sica, F., Acta Crystallogr D Biol Crystallogr, 69, 2403-2411, (2013).
- 13. Russo Krauss I., Spiridonova V., Pica A., Napolitano V., Sica, F., Nucleic Acids Res44, 983-991, (2016).
- 14. Pica A., Russo Krauss I., Parente V., Tateishi-Karimata H., Nagatoishi S., Tsumoto K., Sugimoto N., Sica F., Nucleic Acids Res, in press.

^{1.} Di Cera E., J Thromb Haemost. Suppl 1, 196-202, (2007).